SAN DIEGO, CA – January 30, 2023 – AnaBios is pleased to announce the redesign of their website describing their human tissue platform offerings, including off-the-shelf and custom tissue samples from their industry-leading biorepository, as well as functional assays across the peripheral nervous, central nervous and cardiovascular systems.
AnaBios has long been a leader in providing high quality human tissue samples and cutting-edge functional assays with proven translational value. The new website makes it easier to understand these offerings, bringing true human biology to the bench has never been easier.
“AnaBios has seen tremendous growth across many areas over the last several years and it is time to let others know of our progress,” commented Chris Mathes, Ph.D., Chief Commercial Officer at AnaBios. “We have developed new assays in functional spinal cord and dorsal root ganglion physiology with pharmaceutical industry partners, improved procurement and isolation techniques to generate large batches of highly functional hepatocytes and continue to improve and increase throughput in our cardiovascular platform.”
The launch of the re-designed website is only one of the latest developments from AnaBios. On the heels of investment by Ampersand in mid-2022 and a growing client-base, AnaBios has been able to continue to advance human-derived assay and tissue sample use across the nervous, cardiac, respiratory, liver and other systems.
Located in San Diego, California, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies. AnaBios primarily focuses on areas of high, unmet medical need, including cardiac disease, lung disease, CNS disorders, pain and itch. As a preclinical CRO, AnaBios has the most extensive network of hospitals and transplant centers for obtaining human tissue samples from ethically consented donors for ex vivo analysis. For more information about AnaBios, visit http://www.anabios.com.